Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05520476

Neuroliten MVP System Clinical Observation Study

This is an observational study for data collection from subjects diagnosed with Epilepsy/intractable seizures. The Neuroliten MVP System will not be used for patient management or treatment decisions.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Colorado

Loveland, Colorado, 80538, United States

About this study

Neuroliten MVP system stores the data obtained from wearables, caregivers, and all audio/video recording of seizure activity that the caregiver captures associated with a seizure episode.

The primary objective of this study is to obtain vital signs and neurological indicators via the Neuroliten MVP System to correlate to the onset of seizures that are detected by the observations of family/caregivers.

The secondary objective is to identify the vital signs and/or neurological indicators that are associated with seizure onset.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • An Institutional Review Board (IRB) approved informed consent is signed and dated before any study-related activities.
  • Male and female subjects ages 18 to 75, inclusive.
  • Documented history of at least two (2) seizures per week. Seizures can be generalized and/or focal.
  • Diagnosed with intractable or refractory epilepsy.
  • Have a caregiver/family member who stays with the subject, has the ability to detect seizures, and is willing to provide the information needed for the study.
  • Have implanted vagus nerve stimulation (VNS).
  • Have the ability to understand the requirements of the study and are willing to comply with all study requirements.
  • Must have a working Apple iPhone.

Exclusion criteria

  • Women who are either pregnant or breastfeeding.
  • Subjects unable/unwilling to wear the Apple Watch and EEG Wearable for extended periods.
  • Requires the use of a ventilator.
  • Requires the use of supplemental oxygen.
  • Uses a pacemaker or other electronic neurostimulator, except the VNS.
  • Any medical or surgical condition that in the opinion of the investigator may interfere with participation in the study.

Treatment and study plan

Neuroliten MVP system

Device

The Neuroliten MVP system will be an App that gets uploaded to the patients iPhone from the App Store.

Primary outcomes

  1. Heart Rate

    Time frame: 90 days

    Heart Rate (beats per minute)

  2. Oxygen Saturation

    Time frame: 90 days

    Oxygen Saturation (SpO2 %)

  3. Respiratory Rate

    Time frame: 90 days

    Respiratory Rate (breaths per minute)

  4. Blood Pressure

    Time frame: 90 days

    Blood Pressure (mmHg)

  5. Temperature

    Time frame: 90 days

    Temperature (Fahrenheit)

  6. Brain Signals

    Time frame: 90 Days

    Brain signals obtained using a 14-channel EEG Wearable

Secondary outcomes

  1. Clinical Observations from Caregiver

    Time frame: 90 days

    Caregiver will log details of specific seizure episodes with the following measures:

    • Date, Time and Duration of Seizure
    • Type of seizure (if known)
    • Caregiver's assessment of severity (1-10, 10 being very severe)
    • Cluster of seizures (How many were observed and interval)

Sponsors and collaborators

Lead sponsor

Enliten AI

Industry

Collaborators

  • CSSi Life Sciences

Registry information

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Aug 30, 2022
Registry last updated
Aug 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.